Sell4

NovaBridge Biosciences

NBP

Total Value

$2.6K

Net $2.6K sold

Filing Date

Sep 1, 2026

1 transaction

Sales

$2.6K

1 transaction

Trade Summary

On Aug 30, 2026 through Aug 31, 2026, Xu Cong Claire, Insider, sold $2.6K of NovaBridge Biosciences (NBP) across 1 transaction. The filing covers company securities and reflects net selling of $2.6K. Reported prices ranged from $0.79. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

NBP daily price with the insider's sale marked at $0.79.

Sold near the 6-month low · the stock trades 119% higher today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: Xu Cong Claire
Role: Insider
Location: ROCKVILLE, MD

Filing Details

Filing Date: Sep 1, 2026
Transaction Date: Aug 30, 2026
Accession Number: 0002114309-26-000007
Form Type: 4
Net Trading Amount: -$2.6K

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Aug 30, 2026	NBP common stock	9,382	—	Exercise	—
Aug 31, 2026	NBP common stock	3,282	$0.79	Sale	$2.6K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Aug 30, 2026	NBP derivative	4,079	—	Exercise	—

Want live alerts when Xu Cong Claire trades again?

Download Insider Trades to track NBP, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
(F2)Reported securities are represented by 4,079 ADSs.
(F3)Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
(F4)Reported securities are represented by 133,688 ADSs.
(F5)Reported securities are represented by 1,427 ADSs.
(F6)Reported sales price represents the converted sales price of the ADSs of $1.8186.
(F7)Reported securities are represented by 132,261 ADSs.
(F8)Reported securities represent ADSs.
(F9)On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Cong Claire

(Last)

(First)

(Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE

20850

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Clinical Development

3. Date of Earliest Transaction (Month/Day/Year)
08/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	08/30/2026		M		9,382⁽²⁾	A	⁽³⁾	307,483⁽⁴⁾	D
Ordinary Shares⁽¹⁾	08/31/2026		S		3,282⁽⁵⁾	D	$0.79⁽⁶⁾	304,201⁽⁷⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽³⁾	08/30/2026		M			4,079⁽⁸⁾	⁽⁹⁾	⁽⁹⁾	Ordinary Shares⁽¹⁾	4,079⁽⁸⁾	$0	28,558	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 4,079 ADSs.

3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

4. Reported securities are represented by 133,688 ADSs.

5. Reported securities are represented by 1,427 ADSs.

6. Reported sales price represents the converted sales price of the ADSs of $1.8186.

7. Reported securities are represented by 132,261 ADSs.

8. Reported securities represent ADSs.

9. On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.

	/s/ Kyler Lei, Attorney-in-Fact	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0002114309-26-000007.

NovaBridge Biosciences

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Xu Cong Claire trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4

Price at the Time of the Trade